Baby aspirin, the 81-milligram low-dose tablet millions of people take each morning, prevents blood clots by permanently disabling a key enzyme in platelets. For decades it was handed out almost reflexively to anyone worried about heart attacks or strokes, but the medical consensus on who actually benefits has narrowed considerably since 2018. If you already have heart disease, the case for daily low-dose aspirin remains strong. If you don’t, the math is far less favorable, and recent guideline changes reflect that shift.
How a Tiny Dose Stops Clots
Aspirin works by irreversibly blocking an enzyme called cyclooxygenase, primarily the COX-1 form found in platelets.1PubMed Central. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism COX-1 normally helps produce thromboxane A2, a chemical signal that tells platelets to clump together. When aspirin knocks out COX-1, the platelet can never make thromboxane again for the rest of its roughly ten-day lifespan.2Hematology, ASH Education Program. Does aspirin prevent venous thromboembolism? That is why even a small daily dose steadily reduces the proportion of platelets capable of forming dangerous clots. A full-strength aspirin tablet is 325 milligrams, but 81 milligrams is enough to suppress most thromboxane production without wiping out all prostaglandin activity elsewhere in the body, which is why the low dose became the standard for heart protection.
When the Benefit Is Clear: After a Heart Attack or Stroke
For people who have already had a heart attack, ischemic stroke, or transient ischemic attack, aspirin is one of the most well-supported treatments in medicine. A meta-analysis of trials studying aspirin for secondary stroke prevention found roughly a 13% reduction in the combined risk of another stroke, heart attack, or death from vascular causes.3PubMed Central. Antiplatelet therapy in secondary stroke prevention – state of the art Immediate and long-term aspirin after an ischemic stroke or TIA reduces the chance of another event, and guidelines worldwide uniformly recommend it in this setting.4PubMed. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review
The ADAPTABLE trial, one of the largest randomized studies comparing 81 mg to 325 mg of aspirin in patients with established cardiovascular disease, found no meaningful difference in outcomes between the two doses for either men or women.5JAMA Cardiology. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients In other words, the baby-aspirin dose works just as well as the full-strength tablet for preventing repeat events, and it carries less bleeding risk. That finding helped cement 81 mg as the default dose for secondary prevention.
Primary Prevention: Where the Debate Lives
Primary prevention means taking aspirin when you have never had a heart attack or stroke, hoping to prevent the first one. This is where the story has changed most dramatically. Meta-analyses consistently show that aspirin modestly reduces the risk of a first major cardiovascular event, roughly a 10-14% drop in heart attacks and a similar reduction in ischemic strokes, but those gains are offset by a significant rise in bleeding.6PubMed Central. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups Another large meta-analysis estimated that aspirin increased the risk of major bleeding by about 42%, intracranial hemorrhage by about 33%, and gastrointestinal bleeding by roughly 91%.7PubMed. Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease
When researchers adjusted for the severity of those events, the net clinical benefit in the overall population hovered around zero.6PubMed Central. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups That does not mean aspirin is useless for primary prevention, but it means the benefit is thin enough that bleeding can erase it in many people.
Three major trials reported in 2018 sharpened this picture. The ASCEND trial in people with diabetes and no known vascular disease found that aspirin did reduce serious vascular events but also increased major bleeding, leaving the two effects roughly in balance. The ARRIVE trial in people with multiple cardiovascular risk factors found no reduction in heart attacks or strokes at all, while gastrointestinal bleeding went up. And the ASPREE trial in older adults was stopped early because aspirin had no effect on disability-free survival but increased hemorrhage.8Nature Reviews Cardiology. Role of aspirin in primary prevention of cardiovascular disease
What the Current Guidelines Say
In 2022, the U.S. Preventive Services Task Force updated its aspirin recommendation to reflect the new trial data. For adults aged 40 to 59 with at least a 10% ten-year cardiovascular risk, starting low-dose aspirin is now described as an individual decision rather than a blanket recommendation. For adults 60 and older who have never had a cardiovascular event, the Task Force recommends against initiating aspirin for primary prevention.9U.S. Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication That was a substantial shift from the 2016 version, which had broadly endorsed aspirin for adults 50 to 59 with the same risk threshold and left the door open for those 60 to 69.10JAMA. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement
The guideline language matters. “Individual decision” means you and your doctor weigh your specific risk of a heart attack against your specific risk of a bleed. If you have a strong family history, high blood pressure, elevated cholesterol, and no history of ulcers or bleeding problems, aspirin might still tilt in your favor. If you have a moderate cardiovascular risk but also take blood thinners or have a history of stomach ulcers, the bleeding side of the ledger probably wins.
Older Adults and the ASPREE Warning
The ASPREE trial deserves special attention because its findings were unexpectedly bleak for aspirin in healthy people over 70. More than 19,000 older adults without cardiovascular disease, dementia, or disability were randomized to aspirin or placebo. After a median follow-up of about five years, aspirin provided no benefit in disability-free survival, but it raised the rate of major hemorrhage from about 2.8% to 3.8%.11PubMed. Effect of Aspirin on Disability-free Survival in the Healthy Elderly
Even more troubling, all-cause mortality was higher in the aspirin group, driven largely by cancer-related deaths. Cancer death occurred in about 3.1% of the aspirin group compared with 2.3% in the placebo group.12PubMed. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly This finding remains somewhat puzzling, and researchers have debated whether it reflects a real biological effect or a statistical anomaly in a trial stopped early. It has not been replicated, but it was enough to reinforce the guideline shift against starting aspirin in older adults who have no established cardiovascular disease.
A secondary analysis from the same trial also quantified how GI bleeding risk climbs with age and additional risk factors. For a 70-year-old without aspirin, the five-year absolute risk of serious GI bleeding was about 0.25%. For an 80-year-old taking aspirin with additional risk factors like smoking, hypertension, or kidney disease, that number could reach around 5%.13Gut. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial Age alone is a major bleeding amplifier, which is a big part of why the calculus changes after 60.
Aspirin and Diabetes
People with diabetes face a higher baseline risk of heart attacks and strokes, so you might expect aspirin to be a clear winner in this group. The reality is more ambiguous. The ASCEND trial, which enrolled more than 15,000 people with diabetes and no history of cardiovascular events, found that aspirin reduced serious vascular events by about 12% over an average of seven years. But major bleeding climbed by about 29%, with most of the excess coming from the gastrointestinal tract.14PubMed. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus A meta-analysis incorporating ASCEND and earlier diabetes-focused trials estimated that aspirin use required treating about 95 people for five years to prevent one major cardiovascular event.15PubMed Central. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes
Whether that trade-off makes sense depends on how high someone’s cardiovascular risk really is and how low their bleeding risk is. Current practice leans toward aspirin in people with diabetes who have additional risk factors pushing their cardiovascular danger upward and no major bleeding red flags, but this is exactly the kind of decision that benefits from an honest conversation with a doctor rather than a blanket yes-or-no rule.
Preventing Preeclampsia During Pregnancy
One of the most clear-cut non-cardiac uses for low-dose aspirin is preventing preeclampsia in high-risk pregnancies. A landmark trial published in the New England Journal of Medicine found that aspirin reduced preterm preeclampsia from about 4.3% in the placebo group to 1.6% in the aspirin group, cutting the odds by more than 60%.16PubMed. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia A more recent study confirmed the benefit, showing a roughly 69% relative reduction in preeclampsia when aspirin was started early in pregnancy for high-risk women.17Scientific Reports. Early initiation of low-dose aspirin for the prevention of pre-eclampsia in high-risk pregnancies The typical dose used is 81 to 162 mg daily, started before 16 weeks of gestation in women identified as high-risk through screening. This is now standard practice in obstetric care.
Colorectal Cancer Protection
Beyond cardiovascular disease and preeclampsia, aspirin has drawn attention for its apparent ability to reduce colorectal cancer risk. A pooled analysis of randomized trials found that daily aspirin (doses ranging from 75 to 500 mg) reduced the 20-year risk of colon cancer by about 24% and death from colorectal cancer by about 35%, with longer durations of use linked to greater benefit.18PubMed Central. Aspirin for the prevention of colorectal cancer This evidence has led to U.S. and international guidelines recommending aspirin for colorectal cancer prevention in certain populations.19PubMed Central. Aspirin in the Prevention of Colorectal Neoplasia
There is an important age wrinkle here, though. A study combining large cohort data found that among people 70 and older, aspirin was associated with about a 20% lower risk of colorectal cancer, but only if they had already been taking aspirin regularly before turning 70. People who started aspirin at 70 or later without prior use saw no significant benefit.20JAMA Oncology. Aspirin Use and Risk of Colorectal Cancer Among Older Adults The protective effect also seemed to require at least five years of use before age 70 to kick in. So colorectal cancer prevention is not a reason to start aspirin late in life if you have never taken it before, but it may be an additional argument in favor of continuing if you started younger.
The Bleeding Side of the Ledger
Aspirin’s biggest downside is bleeding, particularly from the gastrointestinal tract. A large prospective study found that regular aspirin users had about a 43% higher risk of GI bleeding compared with non-users, and the risk rose steeply with dose. Women taking more than 14 standard tablets per week had roughly double the risk overall and more than triple the risk of upper GI bleeding.21PubMed Central. Long Term Use of Aspirin and the Risk of Gastrointestinal Bleeding Even at lower doses, certain factors amplify the danger: a prior history of stomach ulcers, taking other anti-inflammatory drugs like ibuprofen or naproxen, and use of the blood thinner clopidogrel.22PubMed. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice
Beyond the gut, low-dose aspirin also raises the risk of intracranial bleeding. A meta-analysis of eight primary prevention trials found that aspirin was associated with about two additional intracranial hemorrhages per 1,000 people treated.23JAMA Neurology. Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease In absolute terms that sounds tiny, but intracranial bleeds are often devastating or fatal. Data from the ASPREE trial in older adults showed that the excess intracranial bleeds from aspirin (29 additional events) actually outnumbered the ischemic strokes it prevented (20 fewer events).24PubMed Central. Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People
Ibuprofen Can Cancel Out Aspirin
If you take baby aspirin for heart protection, ibuprofen can undermine it. Both drugs target the same COX-1 enzyme, and ibuprofen can physically block aspirin from reaching its binding site. A study in the New England Journal of Medicine showed that when ibuprofen was taken before aspirin, it blocked aspirin’s antiplatelet effect entirely. Acetaminophen and diclofenac did not interfere.25PubMed. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin Pharmacokinetic modeling suggests that ibuprofen taken within an hour after aspirin also significantly reduced aspirin’s effect, but waiting at least two hours between aspirin and ibuprofen preserved most of the antiplatelet activity.26PubMed. Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model Naproxen shows a similar interaction; COX-2 selective drugs like etoricoxib and meloxicam do not appear to interfere.27PubMed. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study If you need an occasional pain reliever while on daily aspirin, acetaminophen is the safest choice for preserving aspirin’s heart benefit.
Enteric Coating Does Not Protect the Stomach
Many people assume that enteric-coated aspirin is gentler on the stomach. The coating delays dissolution until the pill reaches the small intestine, bypassing the stomach lining. But a systematic review found that enteric coating was not an effective mechanism for protecting the GI tract. Even short-term use of low-dose enteric-coated aspirin was associated with visible small bowel injury.28PubMed Central. Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review This makes sense because aspirin’s gut damage is mostly systemic, caused by its suppression of protective prostaglandins throughout the body, not just by direct contact with the stomach wall. A large comparative study also found no significant difference in cardiovascular effectiveness or safety between enteric-coated and uncoated aspirin.29PubMed Central. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease If you are concerned about GI bleeding, adding a proton pump inhibitor like omeprazole is far more effective than switching to enteric-coated aspirin.
Why Aspirin Does Not Work for Everyone
A subset of people respond poorly to aspirin despite taking it reliably, a phenomenon sometimes called aspirin resistance. Several biological mechanisms can cause it. Enteric-coated formulations have lower bioavailability and may not fully suppress the target enzyme in some people, particularly those with higher body weight. Rapid platelet turnover in conditions that produce inflammation can introduce fresh, uninhibited platelets into the bloodstream faster than a once-daily dose can keep up. And as discussed, ibuprofen and naproxen can physically block aspirin from binding to its target.30Journal of Thrombosis and Haemostasis. Resistance to antiplatelet drugs: definition, laboratory monitoring, mechanisms and clinical consequences But the most common cause of apparent aspirin resistance is the simplest one: people forget to take it, or stop on their own.
Do Not Stop Aspirin on Your Own
Abruptly stopping aspirin after taking it long-term for cardiovascular protection can be dangerous. A large Swedish population-based study found that people who discontinued aspirin had a 37% higher rate of cardiovascular events compared with those who continued, corresponding to roughly one additional cardiovascular event per year for every 74 people who stop.31PubMed. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study The increased risk appeared shortly after stopping and did not fade over time. A UK study specifically looking at stroke risk found a 40% increase in ischemic stroke or TIA within six months after discontinuation in people who had been taking aspirin for secondary prevention.32PubMed. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study If you and your doctor decide aspirin is no longer appropriate, the transition should be supervised rather than simply stopped one morning.
Dual Antiplatelet Therapy After Stents
After a coronary stent placement or an acute coronary syndrome like a severe heart attack, aspirin alone is often not enough. Combining aspirin with clopidogrel, a second antiplatelet drug, has been shown to reduce the odds of death, re-infarction, and stroke by about 15% in acute coronary syndromes and about 34% in patients who underwent stenting, compared with aspirin alone.33PubMed. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events The trade-off is a significant increase in major bleeding risk with the combination. Dual antiplatelet therapy is typically prescribed for a defined period after a stent, usually six months to a year, after which most patients transition to a single antiplatelet drug for long-term maintenance.
Is Clopidogrel Better Than Aspirin?
An increasingly studied question is whether clopidogrel alone might be preferable to aspirin alone for long-term secondary prevention after stenting. An individual patient data meta-analysis of randomized trials found that clopidogrel monotherapy was associated with fewer major cardiovascular events than aspirin monotherapy over about five and a half years, with no increase in major bleeding.34The Lancet. Clopidogrel versus aspirin monotherapy as secondary prevention in patients with established coronary artery disease: an individual patient data meta-analysis of randomised trials A separate meta-analysis estimated a 31% reduction in major cardiovascular events with clopidogrel versus aspirin after percutaneous coronary intervention, with comparable rates of major bleeding and all-cause death.35PubMed. Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention: a GRADE-assessed meta-analysis with trial sequential analysis These findings are driving a broader conversation about whether aspirin’s long reign as the default antiplatelet drug after stenting may eventually give way to clopidogrel, at least for certain patients. Aspirin’s advantage has always been its low cost and vast evidence base, but if clopidogrel consistently outperforms it without extra bleeding, clinical practice could shift.
Talking to Your Doctor About Stopping (or Starting)
Given the shifting guidelines, many people who started baby aspirin years ago on a doctor’s advice now wonder whether they should still be taking it. Research into how patients prefer to hear that message is itself a growing area. A recent study found that about 62% of older adults preferred a “therapeutic pause” approach, where aspirin is temporarily held with a plan to follow up with their primary care doctor, rather than a blunt statement that aspirin is no longer needed.36PubMed Central. Navigating Medication Risk in the ED: Communication Preferences of Older Adults Regarding Deprescribing The least popular approach was a firm directive to stop. People who have taken aspirin for years often feel protective of it, and the framing of the conversation matters for whether they actually follow through. If you are in the group that the current guidelines advise against starting aspirin, or if your risk profile has changed since you first began, raising the topic at your next visit is worthwhile. Aspirin may be tiny, over-the-counter, and inexpensive, but whether it belongs in your daily routine depends on a balance sheet that looks different for every person and can change over time.